Locally advanced breast cancers are more likely to present as interval cancers: Results from the I-SPY 1 TRIAL (CALGB 150007/150012, acrin 6657, interSPORE trial)

Breast Cancer Research and Treatment

Volumn 132, Issue 3, 2012, Pages 871-879

  Lin, Cheryl ^a   Buxton, Meredith Becker ^a   Moore, Dan ^b   Krontiras, Helen ^c   Carey, Lisa ^d   De Michele, Angela ^e   Montgomery, Leslie ^f   Tripathy, Debasish ^g   Lehman, Constance ^h   Liu, Minetta ⁱ   Olapade, Olufunmilayo ^j   Yau, Christina ^a   Berry, Donald ^k   Esserman, Laura J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Interval cancer; Neoadjuvant; Screening

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER LOCALIZATION; CANCER SCREENING; CANCER SIZE; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MENOPAUSE; OCCULT CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; BREAST TUMOR; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DELAYED DIAGNOSIS; EARLY DIAGNOSIS; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PATHOLOGY; RADIOGRAPHY; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DELAYED DIAGNOSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM GRADING; TUMOR BURDEN;

EID: 84865188320     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1670-4     Document Type: Article

References (29)

1. Esserman L, Shieh Y, Thompson I (2009) Rethinking screening for breast cancer and prostate cancer. JAMA 302(15):1685-1692
2. Elmore JG, Armstrong K, Lehman CD, Fletcher SW (2005) Screening for breast cancer. JAMA 293(10):1245-1256
3. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L, Force USPST (2009) Screening for breast cancer: an update for the U. S. preventive services task force. Ann Intern Med 151(10):727-737, W237-742
4. Shapiro S, Venet W, Strax P, Venet L, Roeser R (1982) Ten-to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 69(2):349-355
5. Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, Ljungberg O, Ranstam J, Sigfusson B (1988) Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 297(6654):943-948
6. Verbeek AL, Hendriks JH, Holland R, Mravunac M, Sturmans F, Day NE (1984) Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. Lancet 1(8388):1222-1224
7. de Waard F, Collette HJ, Rombach JJ, Baanders-van Halewijn EA, Honing C (1984) The DOM project for the early detection of breast cancer, Utrecht, The Netherlands. J Chronic Dis 37(1):1-44
8. Ikeda DM, Andersson I, Wattsgard C, Janzon L, Linell F (1992) Interval carcinomas in the Malmo mammographic screening trial: radiographic appearance and prognostic considerations. AJR Am J Roentgenol 159(2):287-294
9. Bordas P, Jonsson H, Nystrom L, Lenner P (2009) Interval cancer incidence and episode sensitivity in the Norrbotten Mammography Screening Programme, Sweden. J Med Screen 16(1):39-45
10. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval-and screen-detected cancers. J Natl Cancer Inst 91(23):2020-2028
11. Gilliland FD, Joste N, Stauber PM, Hunt WC, Rosenberg R, Redlich G, Key CR (2000) Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 92(9):743-749
12. De Groote R, Rush BF Jr, Milazzo J, Warden MJ, Rocko JM (1983) Interval breast cancer: a more aggressive subset of breast neoplasias. Surgery 94(4):543-547
13. Heuser L, Spratt JS Jr, Polk HC Jr, Buchanan J (1979) Relation between mammary cancer growth kinetics and the intervals between screenings. Cancer 43(3):857-862
14. Heuser L, Spratt JS, Polk HC Jr (1979) Growth rates of primary breast cancers. Cancer 43(5):1888-1894
15. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752
16. Peppercorn J, Perou CM, Carey LA (2008) Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 26(1):1-10
17. Cianfrocca M, Gradishar W (2009) New molecular classifications of breast cancer. CA Cancer J Clin 59(5):303-313
18. Esserman L et al (2009) Poster session: Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). ASCO Annual Meeting, Orlando, FL, May 29-31
19. Buxton ELMB (2005) The challenge of integrating information and improving care for breast cancer: The I SPY Trial informatics effort. In: Perry MC (ed) American society of clinical oncology. Lisa Greaves, Orlando
20. Klemi PJ, Joensuu H, Toikkanen S, Tuominen J, Rasanen O, Tyrkko J, Parvinen I (1992) Aggressiveness of breast cancers found with and without screening. BMJ 304(6825):467-469
21. Schroen AA, Wobbes T, van der Sluis RF (1996) Interval carcinomas of the breast: a group with intermediate outcome. J Surg Oncol 63(3):141-144
22. Frisell J, von Rosen A, Wiege M, Nilsson B, Goldman S (1992) Interval cancer and survival in a randomized breast cancer screening trial in Stockholm. Breast Cancer Res Treat 24(1):11-16
23. Brekelmans CT, Peeters PH, Deurenberg JJ, Collette HJ (1995) Survival in interval breast cancer in the DOM screening programme. Eur J Cancer 31 A (11): 1830-1835
24. Cowan WK, Angus B, Gray JC, Lunt LG, al-Tamimi SR (2000) A study of interval breast cancer within the NHS breast screening programme. J Clin Pathol 53(2):140-146
25. Taylor R, Page A, Bampton D, Estoesta J, Rickard M (2004) Age-specific interval breast cancers in New South Wales and meta-analysis of studies of women aged 40-49 years. J Med Screen 11(4):199-206
26. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ (2009) I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86(1):97-100
27. I-SPY 2 TRIAL [www.ispy2.org]
28. Granader EJ, Dwamena B, Carlos RC (2008) MRI and mammography surveillance of women at increased risk for breast cancer: recommendations using an evidence-based approach. Acad Radiol 15(12):1590-1595
29. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, De Boer G, Yaffe MJ, Messner SJ et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292(11):1317-1325